SIRT6 expression predicted a 6.988 fold greater risk of death of osteosarcoma patients (95% CI, 1.439–33.930; P = 0.016) and had a 6.930 fold greater risk of relapse of tumor or death of patients (95% CI, 1.727–27.814; P = 0.006) (Table 4). Here, SIRT6 is linked to neoplasm.